Cargando…

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY

Detalles Bibliográficos
Autores principales:	Agrawal, Manasi, Zhang, Xian, Brenner, Erica J., Ungaro, Ryan C., Kappelman, Michael, Colombel, Jean Frederic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2021
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108238/ http://dx.doi.org/10.1016/S0016-5085(21)01515-8

Ejemplares similares

Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS
por: Sperger, John, et al.
Publicado: (2021)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
por: Spiera, Emily, et al.
Publicado: (2022)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE
por: Ricciuto, Amanda, et al.
Publicado: (2021)

IBD in the COVID-19 era: the value of international collaboration
por: Brenner, Erica J, et al.
Publicado: (2020)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

Sa1061: CROSS-SECTIONAL AND LONGITUDINAL ASCERTAINMENT OF PATIENTS WITH IBD'S PERCEPTIONS AND EXPERIENCES DURING COVID-19: CLAPPED COVID-19
por: Lee, Hanbich, et al.
Publicado: (2022)

Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD
por: Sperger, John, et al.
Publicado: (2021)

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients
por: Sperger, John, et al.
Publicado: (2021)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION)
por: Doherty, Jayne, et al.
Publicado: (2022)

Fr228 AN INTERNATIONAL REPORTING REGISTRY OF PATIENTS WITH CELIAC DISEASE AND COVID-19: INITIAL RESULTS FROM SECURE-CELIAC
por: Uche-Anya, Eugenia, et al.
Publicado: (2021)

Sa1055: PERCEPTIONS OF ACCESSING CARE AMONG IBD PATIENTS DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19
por: Taxonera, Carlos, et al.
Publicado: (2022)

Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS
por: Livanos, Alexandra E., et al.
Publicado: (2021)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

EP1021: CHANGES IN THE NEEDS OF IBD PATIENTS FOR TREATMENT BEFORE AND AFTER THE COIVD19 EPIDEMIC (ANALYSIS USING TWITTER DATA)
por: Fuchigami, Ayako
Publicado: (2022)

Mo1086: MENTAL HEALTH IN IBD DURING THE COVID-19 PANDEMIC: ACCESS TO MENTAL HEALTH CARE AND EXPOSURE TO PANDEMIC NEWS
por: Shaffer, Seth R., et al.
Publicado: (2022)

Sa081 FEAR OF COVID-19 AMONG IBD PATIENTS ACCORDING TO EMPLOYMENT STATUS, EDUCATION AND RESIDENCE AND COMPARED TO OTHER GI CONDITIONS
por: Lo, Bobby, et al.
Publicado: (2021)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Su095 REAL-TIME DEFORMABILITY CYTOMETRY (RT-DC) REVEALS NOVEL CORRELATIONS BETWEEN INFLAMMATION AND MECHANICAL PROPERTIES OF NEUTROPHILS IN IBD PATIENTS
por: Ganzleben, Ingo, et al.
Publicado: (2021)

Sa127 AN IBD-RISK VARIANT IN PTPN2 PROMOTES CELLULAR UPTAKE OF SARS-COV-2, WHICH IS MITIGATED BY THE JAK INHIBITOR TOFACITINIB
por: Spalinger, Marianne, et al.
Publicado: (2021)

855 PATIENT-LED REMOTE INTRACAPILLARY PHARMACOKINETIC SAMPLING (FINGERPRICKS): VALIDATION AND ACCEPTABILITY FOR HOME THERAPEUTIC DRUG MONITORING IN PATIENTS WITH IBD IN THE COVID-19 PANDEMIC
por: Chee, Desmond, et al.
Publicado: (2021)

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Sa1050: COVID-19 VACCINATION RATES AND POST-VACCINATION INFECTION RISK IN IBD PATIENTS TREATED WITH DISEASE MODIFYING AGENTS: A RESEARCH NETWORK ANALYSIS
por: Chumbe, Julton Tomanguillo, et al.
Publicado: (2022)

Fr094 UTILITY OF COVID-19 ANTIBODY TESTING FOR PRE-ENDOSCOPY SCREENING
por: Noorali, Anika, et al.
Publicado: (2021)

Fr195 PERCEPTIONS OF COVID-19 IN THE EOSINOPHILIC ESOPHAGITIS POPULATION
por: Thanawala, Shivani U., et al.
Publicado: (2021)

Fr090 IMPACT OF THE COVID-19 PANDEMIC ON ENDOSCOPY CANCELLATIONS
por: Wang, Connie W., et al.
Publicado: (2021)

Fr002 EFFECT OF THE COVID-19 PANDEMIC ON ACUTE GASTROINTESTINAL BLEEDING
por: Reddy, Sumana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_onotfujips1vketb7shggphmcl